Hematopoietic stem cell transplantation (HSCT) remains the only curative option for patients
with thalassemia. Current results of transplantation in patients aged less than 17 years from
matched related donors offer 80% to 87% probability of cure according to risk classes. Adult
thalassemics treated with myeloablative conditioning continue to have inferior results
because of their advanced stage of disease. With the introduction of high-resolution tissue
typing techniques transplant centres worldwide are able to offer allogeneic HSCT to a much …